Industry
Foghorn cuts 40% of workforce after Lilly collaboration ends
Foghorn Therapeutics is laying off 40% of its workforce after Eli Lilly ended their drug development collaboration.
The original reports on this story are listed below.
Industry
Foghorn Therapeutics is laying off 40% of its workforce after Eli Lilly ended their drug development collaboration.
The original reports on this story are listed below.

Outbreaks
The unvaccinated Lancaster County resident is Pennsylvania’s fifth reported measles-associated death this year.

Diabetes and obesity
The highest-dose combination produced greater weight loss than tirzepatide alone, but up to 27% of participants stopped treatment because of side effects.

Drugs and FDA
In the 76-week trial, gastrointestinal side effects led 18% of participants in each survodutide dose group to stop treatment.
This Week in Medicine
The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.
Free. No spam. Unsubscribe anytime.